Biotech M&A Q1 2026 Report: 16 Deals, $44B in Value, and What It Signals
A Q1 2026 biotech M&A recap covering 16 control transactions, the biggest biopharma acquisitions, therapeutic-area trends, and what the deal tape says about where buyers are paying up.
Stay up to date with our live tracker of biotech/biopharma IPOs in 2026 — therapeutic area, lead asset + phase at IPO, pricing date, proceeds and valuation, plus aftermarket performance. Updated Weekly.
Live tracker of biotech/biopharma M&A in 2026: target, acquirer, announced date, deal value, upfront, structure, premium, and rationale. Updated weekly.
Stay up to date with our live tracker of biotech/biopharma licensing + partnering deals in 2026 — upfronts, milestones, royalties, rights/territory, and a one-line “why it matters.” Updated weekly.
Track February 2026 biotech/biopharma licensing + partnering deals — upfronts, milestones, royalties, rights/territory, and a one-line “why it matters.”
